Alpine Institute’s Post

📢 Excited to announce the release of "Mechanisms of Disease Pathogenesis in Multiple Sclerosis," edited by Francisco Javier Quintana! This comprehensive book delves into MS, its clinical features, available biomarkers, and the mechanisms driving disease pathogenesis. It also covers the influence of genetic and environmental factors and highlights novel therapies for disease management. A must-read for neurologists, neuroimmunologists, and researchers dedicated to understanding neurodegeneration. Get your copy today: https://bit.ly/4b5WNGK #MultipleSclerosis #Neurodegeneration #NewBook #Neuroscience #ElsevierBooks

The Continuous Paired Associate Learning Test (CPAL) is a digital, non-verbal, pattern space association learning test with strong validity to human learning networks 🧠. The assessment is highly sensitive to disruptions of human memory systems and is effective across many diseases and disorders. Notable use cases for CPAL include the Australian Imaging, Biomarkers, and Lifestyle (AIBL) study, the PERSPECTIVE sacubitril/valsartan trial, and an ongoing pivotal, phase 3 Alzheimer’s disease trial. More details on CPAL and the many other digitial cognitive assessments on the Cogstate platform can be found here 👉 https://lnkd.in/e53Wt6tC #Cognition #BrainHealthForAll #Neuroscience #ClinicalTrials

Live-cell analysis of 3D models is revolutionizing our understanding of this devastating condition by providing more biologically relevant insights. In addition to better in-vitro models, improved assays and technologies that can capture the data generated by these models are vital to accelerate therapeutic developments for Alzheimer's Disease. Download this white paper to learn how live cell analysis of 2D and 3D models provides a better understanding of the mechanism of AD by addressing the limitations of traditional methods. Read now: https://ow.ly/kqnY50Q8T8b #alzheimers #neuroscience #3dcellmodels #livecellanalysis

A promising target in CNS drug development in neurodegeneration!

Ncardia webinar today @10am featuring #ipscs for devt of treatments for #proteinopathies:

🤔With over 55 million people worldwide affected by Alzheimer's and no cure in sight, raising awareness is crucial. September 21th was World Alzheimer's Day, so let's talk about research and hope for patients! 🧠At ETAP-Lab, we're dedicated to developing innovative models of neurodegenerative diseases, from in vitro to in vivo, to accelerate #preclinicalresearch into Alzheimer's drugs. 👩🔬👨🔬Our scientists will be presenting our latest advances at #Neuroscience #SFN2024 in Chicago with our 2 posters. ▶️ Stay tuned for insights into our innovations in #BrainOnChip technology, #neuroinflammation models and #oligomers 👉And to learn more about the disease, visit Alzheimer Europe website: https://lnkd.in/eJJiCH2h #WorldAlzheimersDay #HealthTech #AlzheimersResearch

On the occasion of #RareDiseaseDay on February 29th, you can find in this Neurological Disease Modeling hub some interesting webinars, podcasts, protocols,... in order to have an idea what the researchers are doing in this field. #neuroscience #organoids #research #neurodegenerativediseases

🧠 Exciting Breakthrough in Alzheimer's Research 🌟 Researchers have identified five distinct subtypes of Alzheimer's disease, a major leap forward in understanding and treating this complex condition. This discovery, involving an international team of neuroscientists, reveals unique molecular processes and genetic profiles for each subtype. This new perspective on Alzheimer's disease opens the door to more targeted and effective treatment strategies. It's not just a single disease; it's five distinct conditions with their own characteristics and treatment needs. Read more about this groundbreaking research in the detailed article from New Atlas: https://lnkd.in/ekx9UgP6 #AlzheimersResearch #MedicalInnovation #Neuroscience #Healthcare

Maximise your impact through irresistible scientific visualisation. Our expertise lies in telling strategic visual stories that engage your target audience. We don't just go through the motions, but delve deep into every project to get the most out of the collaboration. Want us on your team? 🤙 ——— Follow our journey as we bring world-changing innovations to life. Go to our page (Sensu), click follow (➕), and hit the bell (🔔). ——— 🧠 https://lnkd.in/eFyJgix2 Synaptic Systems GmbH, Histosure by Synaptic Systems #CreativeAgency #3Danimation #Biotech #ScienceAndTechnology #Immunology #CancerResearch #Neuroscience

🧠 Groundbreaking research offers new insights into Alzheimer’s disease (AD) progression. A study suggests that glucose metabolism in the posterior cingulate cortex (PCC), measured by the standard uptake value ratio (SUVR) from FDG PET imaging, could serve as a supplementary biomarker alongside amyloid-β (Aβ) and tau. Kaplan-Meier survival analyses indicate that combining PCC SUVR with CSF Aβ42 and ptau-181 enhances the predictive performance for the progression from cognitively unimpaired (CU) to AD. This correlation could revolutionize early prediction and prevention strategies in neurodegenerative diseases. #AlzheimersResearch #Neuroscience #Biomarkers https://lnkd.in/g4XcszB9